AXIM — AXIM BIOTECHNOLOGIES, INC.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1514946 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 0 | 0 | -21,656 | 370,171 | — | 2,803 | — |
| Mar 2025 | 0 | 0 | -268,739 | -234,253 | 3,346,106 | 7,184 | 13,983,424 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-1,347,180
Investing CF
$0
Financing CF
$1,338,418
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.00
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-75,793,392
Inventory
$0
Receivables
—
ST Investments
—
EBIT TTM
$220,218
Pretax Income TTM
$135,918
Interest Exp TTM
$84,300
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$92,898
EBITDA
$-1,883,836
Free Cash Flow
$-2,999,857
Enterprise Value
$7,942,326
Total Cash
$6,044
Total Debt
$6,782,759
Shares Out
349,804,452
Trailing EPS
$0.00
Book Value
$-0.03
ROE
—
ROA
-36.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 70,458 | -1,763,079 | -3,520,471 | 3,447,296 | 13,866,861 | -10,419,565 | -855,058 |
| Dec 2023 | 39,518 | -2,750,839 | -8,059,682 | 4,121,548 | 11,778,195 | -7,656,647 | -1,030,500 |
| Dec 2022 | 8,875 | -4,652,772 | -6,242,949 | 4,212,035 | 9,037,447 | -4,825,412 | -2,044,326 |
| Dec 2021 | 60,460 | -7,728,565 | -16,032,305 | 5,323,435 | 7,661,635 | -2,338,200 | -2,486,765 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.06T | $1183.46 | — |
| JNJ | JOHNSON & JOHNSON | $653.61B | $271.22 | — |
| ABBV | AbbVie Inc. | $467.12B | $264.34 | — |
| MRK | Merck & Co., Inc. | $367.07B | $148.78 | — |
| NVS | NOVARTIS AG | $276.48B | $145.46 | — |
News headlines (Yahoo Finance, 1h cache)
Exclusive: Axiom CEO on Hong Kong IPO plans, path to public markets
2026-07-23 15:13 · Yahoo
AXIM Biotechnologies, Inc. and Medical Marijuana, Inc. Enter Into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids
2026-01-29 14:00 · Yahoo
Medical Marijuana, Inc. and AXIM Biotechnologies, Inc. Enter Into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids
2026-01-29 14:00 · Yahoo
AXIM Biotechnologies Engages 624 Advisors, Owned and Managed by Dr. Alan J. Touch, Innovator and Global Regulatory Leader, as Chief Medical & Regulatory Affairs Advisor
2026-01-20 14:00 · Yahoo
AXIM Biotechnologies, Inc. Announces Exclusive Distribution Agreement With VisionPlus Corp. for TearScan(R) Lactoferrin and IgE Diagnostic Tests in South Korea
2025-10-23 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.